Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Sales in the U.S., where Pfizer's patent expired Nov. 30 for Lipitor, the top-selling drug in history, fell to $5.95 billion, from $7.02 billion. International sales edged up 1%, to $9.45 billion.

The Case for Pfizer. Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of ...

Over the past decade, Pfizer has strengthened its R&D pipeline through M&A deals and clinical trial success. Pfizer’s key vaccine candidates in late-stage studies are its C. difficile vaccine and an ...